ArticleBreast cancer research : BCR2005
Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.
Article in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 126 citations in OpenAlex.
- Lidocaine effects on neutrophil extracellular trapping and angiogenesis biomarkers in postoperative breast cancer patients with different anesthesia methods: a prospective, randomized trial.BMC anesthesiology · 2024Trial
- Effects of indoor air pollution exposure on lung function of children in selected schools in Kigali, Rwanda.Scientific reports · 2025Article
- Propofol regulates the progression of hepatocellular carcinoma via the POLR2L/TGF-β signaling pathway.Translational cancer research · 2024Article
- Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer.Cell cycle (Georgetown, Tex.) · 2024Article
- Promising Effects ofMolecules (Basel, Switzerland) · 2023Review
- Effect of equipotent doses of propofol and sevoflurane on endoplasmic reticulum stress during breast cancer surgery.Korean journal of anesthesiology · 2022Article
- Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment.Journal of nanobiotechnology · 2022Article
- Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy.Molecules (Basel, Switzerland) · 2021Review
- Harnessing cancer immunotherapy during the unexploited immediate perioperative period.Nature reviews. Clinical oncology · 2020Review
- Review
- Surgical stress and cancer progression: the twisted tango.Molecular cancer · 2019Review
- Use of a colorimetric assay to evaluate the proliferation of canine mammary tumor cells exposed to propofol.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2019Article
- Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Effects of propofol on human cholangiocarcinoma and the associated mechanisms.Experimental and therapeutic medicine · 2019Article
- Effect of Propofol on breast Cancer cell, the immune system, and patient outcome.BMC anesthesiology · 2018Review
- Propofol Inhibits HeLa Cells by Impairing Autophagic Flux via AMP-Activated Protein Kinase (AMPK) Activation and Endoplasmic Reticulum Stress Regulated by Calcium.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.BMC anesthesiology · 2017Article
- Cell membrane modulation as adjuvant in cancer therapy.Cancer treatment reviews · 2017Review
- Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression.Molecular medicine reports · 2015Article
- Biophysical Interactions of Novel Oleic Acid Conjugate and its Anticancer Potential in HeLa Cells.Journal of fluorescence · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpidemiological evidence strongly links fish oil, which is rich in docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), with low incidences of several types of cancer. The inhibitory effects of omega-3 polyunsaturated fatty acids on cancer development and progression are supported by studies with cultured cells and animal models. Propofol (2,6-diisopropylphenol) is the most extensively used general anesthetic-sedative agent employed today and is nontoxic to humans at high levels (50 microg/ml). Clinically relevant concentrations of propofol (3 to 8 microg/ml; 20 to 50 microM) have also been reported to have anticancer activities. The present study describes the synthesis, purification, characterization and evaluation of two novel anticancer conjugates, propofol-docosahexaenoate (propofol-DHA) and propofol-eicosapentaenoate (propofol-EPA).
methodsThe conjugates linking an omega-3 fatty acid, either DHA or EPA, with propofol were synthesized and tested for their effects on migration, adhesion and apoptosis on MDA-MB-231 breast cancer cells.
resultsAt low concentrations (25 microM), DHA, EPA or propofol alone or in combination had minimal effect on cell adhesion to vitronectin, cell migration against serum and the induction of apoptosis (only 5 to 15% of the cells became apoptotic). In contrast, the propofol-DHA or propofol-EPA conjugates significantly inhibited cell adhesion (15 to 30%) and migration (about 50%) and induced apoptosis (about 40%) in breast cancer cells.
conclusionThese results suggest that the novel propofol-DHA and propofol-EPA conjugates reported here may be useful for the treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.